Sclerosing Cholangitis as Immune-Related Adverse Event Caused by Nivolumab and Ipilimumab Therapy

Shiho Katsuie,Kenta Nakamura,Rika Suzuki, Tatsuya Nihei,Yuko Takazawa,Toshikazu Omodaka,Yukiko Kiniwa, Shun-ichi, Wakabayashi, Tomoo Yamazaki,Ryuhei Okuyama

semanticscholar（2021）

引用 0|浏览0

暂无评分

摘要

Immune checkpoint inhibitors (ICIs) cause several immune-related adverse events (irAEs); however, few studies have described sclerosing cholangitis (SC) and its therapeutics.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要